References
- Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect 2004;80:255-63
- A Complex Picture. HIV and other sexually transmitted infections in the United Kingdom: 2006. Health Protection Agency, London: UK Collaborative Group for HIV and STI Surveillance, 2006. Available at: http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1196942145471?p=1158945066450 [Last accessed 18 April 2008]
- Trends in genital warts and genital herpes diagnoses in the United Kingdom. Health Protection Agency. Health Protection Report,Volume 1, Number 35, 31 August 2007. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1203084376408 [Last accessed 18 April 2008]
- Giuliani M, Suligoi B. L’infezione da HPV e le altre MST in Italia. From: Human Papilloma Virus: Le acquisizioni di base e la ricerca clinica, 2005:7-14
- Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006;12:5
- von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-603
- Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27
- Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403
- Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571-8
- Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24S3:S3/35-S3/41
- Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician 2004;70:2335-42
- Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008: published online 13 March 2008
- FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27
- Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43
- Monsonégo J, Breugelmans JG, Bouée S, et al. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. [Article in French] Gynecol Obstet Fertil 2007;35:107-13
- van der Meijden WI, Notowicz A, Blog FB, et al. A retrospective analysis of costs and patterns of treatment for external genital warts in the Netherlands. Clin Ther 2002;24:183-96
- Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501-8
- Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70
- Vittori G, Matteelli A, Boselli F. et al.A new approach to estimate genital warts incidence and prevalence in the Italian general female population. It J Gynaecol Obstet 2008;20:33-42
- Dasbach EJ, Insinga RP, Elbasha EH. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008: doi: 10.1111/j.1471-0528.2008.01743.x